Related Experiment Video
Updated: Feb 21, 2026
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019
Recent progress in the treatment of pediatric lymphoma in Japan
1Yamagata University Faculty of Medicine, Pediatrics.
Insights
Pediatric non-Hodgkin lymphoma (NHL) survival rates have significantly improved, with advanced stages now exceeding 80% 5-year event-free survival. Future research should focus on refractory cases and rare lymphoma types.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Research
Background:
- Pediatric non-Hodgkin lymphoma (NHL) treatment and prognosis have seen dramatic improvements over the past 30 years.
- Localized NHL (stages I-II) now has a 95%-100% 5-year event-free survival (EFS) rate.
- Advanced-stage NHL (stages III-IV) prognosis has doubled to over 80% 5-year EFS.
Purpose of the Study:
- To describe key steps in clinical studies for pediatric lymphoma.
- To highlight the role of organizational frameworks like the Japanese Pediatric Leukemia Lymphoma Study Group.
- To identify future research directions for pediatric lymphoma.
Main Methods:
- Review of clinical study steps for pediatric lymphoma by histologic entity.
- Examination of advancements in chemotherapy and organizational frameworks.
- Analysis of survival data for localized and advanced-stage disease.
Main Results:
- Significant improvements in 5-year EFS rates for both localized and advanced pediatric NHL.
- Hodgkin lymphoma shows an approximately 80% 10-year EFS rate.
- The Japanese Pediatric Leukemia Lymphoma Study Group has played a crucial role since 2003.
Conclusions:
- Pediatric lymphoma treatment has advanced significantly due to chemotherapy and collaborative study frameworks.
- Future efforts must focus on developing treatments for refractory/recurrent diseases and validating reduced chemotherapy for low-risk patients.
- Global collaboration is needed to clarify conditions and establish standard therapies for rare lymphoma types.
Abstract:
Both treatment and prognosis of pediatric non-Hodgkin lymphoma (NHL) have improved dramatically in the last 30 years. Currently, localized or limited-stage NHL (stage I to II) has an approximately 95%-100% 5-year event-free survival (EFS) rate. Furthermore, the prognosis for children with advanced-stage disease (stage III to IV) has doubled from approximately 40% 5-year EFS 30 years ago to more than 80%. Hodgkin lymphoma is also known to have around 80% 10-year EFS rate. These were accomplished not only by the advancement of chemotherapy drugs but also with the global development of organizational frameworks for pediatric clinical study. The Japanese Pediatric Leukemia Lymphoma Study Group is one of such frameworks that was organized in 2003, and it has been playing a great role in Japan ever since. In this study, I described some of the main steps of clinical studies for pediatric lymphoma according to each histologic entity. In the future, however, an effective treatment for refractory or recurrent diseases should be developed. In addition, a precise validation for low-risk patients who need reduced chemotherapy should be performed. Further clarifications on the conditions of patients with rare type lymphoma and an establishment of a standard therapy for them through a collaborative study on a global scale are needed.
More Related Videos
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024